| Abstract | Cilj istraživanja bio je analizirati distribuciju HR-HPV tipova u bolesnica s HSIL i
karcinomom vrata maternice, te utvrditi učestalost HPV 16 genomskih inačica u
premalignim i malignim promjenama.
HPV-DNA je izolirana iz 373 uzorka pacijentica s HSIL i karcinomom vrata maternice.
Najčešći tip u HSIL bio je HPV 16 (57,9%), zatim HPV 31, HPV 33, HPV 58, HPV 52,
HPV 18 i HPV 45 (12,8%, 6,8%, 6,4%, 5,9%,4,6% i 3,2%). HPV 16 je bio dominantan
u karcinomu pločastih stanica (66,7%), ostali tipovi su bili: HPV 31, HPV 45, HPV 18 i
HPV 33 (14,5%, 7,2%, 7,2% i 5,8%) uzorka. U adenokarcinomu HPV 16 bio je u
50,0%, HPV 18 u 41,7% a HPV 45 u 5,6% uzoraka. Određene su HPV16 inačice za
130 HPV16 pozitivnih uzoraka. U 74 uzorka HSIL-a pronađena je 41 inačica, 98,6%
pripadalo je europskoj grani, a jedna (1,4%) afričkoj grani. Promatrajući uzorke
karcinoma, 95% izolata svrstano u 41 varijantu pripadalo je europskoj grani, jedan
izolat (2,5%) u Sjeverno Američkoj i jedan (2,5%) azijsko-američkoj grani.
HPV 16 je bio dominantan. HPV 16 varijante dominantno pripadaju europskoj grani
bez obzira na patohistološku dijagnozu. Sveobuhvatnim cijepljenjem devetvalentnim
HPV cjepivom mogla bi se prevenirati 91,5% premalignih i malignih llezija vrata
maternice u Hrvatskoj. |
| Abstract (english) | The aim of the study was to analyze the distribution of HR-HPV types in patients
with HSIL and cervical carcinoma and to determine the incidence of HPV 16
genomic variants in premalignant and malignant changes.
HPV-DNA was isolated from 373 samples from patients with HSIL and cervical
carcinoma. The most common type in HSIL was HPV 16 (57.9%), followed by
HPV 31, HPV 33, HPV 58, HPV 52, HPV 18 and HPV 45 (12.8%, 6.8%, 6.4%,
5.9%, 4.6% and 3.2%). HPV 16 was dominant in squamous cell carcinoma
(66.7%), other types were: HPV 31, HPV 45, HPV 18 and HPV 33 (14,5%,
7,2%, 7,2% and 5,8%). In adenocarcinoma HPV 16 was in 50.0%, HPV 18 in
41.7% and HPV 45 in 5.6% samples. HPV16 variants were determined for 130
HPV16 positive samples. In 74 HSIL samples 41 variants were found, 98.6%
belonged to the European branch, one (1.4%) to the African branch. Observing
carcinoma samples, 95% isolates grouped in 41 variants belonged the
European branch, one isolate (2.5%) the North American, and one (2.5 %) the
Asian-American branch.
HPV 16 was dominant. HPV 16 variants dominantly belong to European branch
regardless of pathohistological diagnosis. Comprehensive vaccination with the nine-valent HPV vaccine could prevent 91.5% of premalignant and malignant
cervical lesions in Croatia. |
